Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors

MLA

Alexandre Fabre, et al. “Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors.” C25. CLINICAL AND TRANSLATIONAL STUDIES IN RARE LUNG DISEASE, May 2019. EBSCOhost, https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4376.

APA

Alexandre Fabre, S. Leroy, Lisa R. Forbes, V. Barlogis, M. Guesmi, Jennifer W. Leiding, Tiphanie P Vogel, J.-C. Dubus, C.H. Marquette, L. Giovannini-Chami, S. Marchal, M.D. Silva Carmona, & M. Baravalle. (2019). Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors. C25. CLINICAL AND TRANSLATIONAL STUDIES IN RARE LUNG DISEASE. https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4376

Chicago

Alexandre Fabre, S. Leroy, Lisa R. Forbes, V. Barlogis, M. Guesmi, Jennifer W. Leiding, Tiphanie P Vogel, et al. 2019. “Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors.” C25. CLINICAL AND TRANSLATIONAL STUDIES IN RARE LUNG DISEASE, May. doi:10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4376.